Healthcare provider profile · identity verified

Richard Steven Smith, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MILTON, PA · NPI 1457342883

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Richard Steven Smith, MD received $13.98 in general payments during 2025 across 1 reported records.

Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$13.98

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$13.98	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$13.98	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$13.98	1	2025
Source payment records 2025-04-02 · Novo Nordisk Inc · $13.98 · Open Payments source
Rybelsus Normalized: rybelsus	Drug	Novo Nordisk Inc	$13.98	1	2025
Source payment records 2025-04-02 · Novo Nordisk Inc · $13.98 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	49	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	49	12

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	932	243
Levothyroxine Sodium	Levothyroxine Sodium	515	137
Lisinopril	Lisinopril	463	131
Omeprazole	Omeprazole	409	121
Metoprolol Succinate	Metoprolol Succinate	403	106
Losartan Potassium	Losartan Potassium	395	93
Amlodipine Besylate	Amlodipine Besylate	393	100
Rosuvastatin Calcium	Rosuvastatin Calcium	342	100
Furosemide	Furosemide	305	68
Metformin Hcl	Metformin Hcl	288	77
Tramadol Hcl	Tramadol Hcl	260	90
Gabapentin	Gabapentin	238	58
Albuterol Sulfate Hfa	Albuterol Sulfate	235	116
Tamsulosin Hcl	Tamsulosin Hcl	233	65
Hydrochlorothiazide	Hydrochlorothiazide	229	64
Eliquis	Apixaban	222	55
Pantoprazole Sodium	Pantoprazole Sodium	209	49
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	167	165
Fluoxetine Hcl	Fluoxetine Hcl	163	43
Metoprolol Tartrate	Metoprolol Tartrate	158	40
Simvastatin	Simvastatin	155	43
Metformin Hcl Er	Metformin Hcl	146	40
Methylprednisolone	Methylprednisolone	139	104
Jardiance	Empagliflozin	133	31
Ezetimibe	Ezetimibe	132	33
Trazodone Hcl	Trazodone Hcl	126	30
Alendronate Sodium	Alendronate Sodium	123	34
Pregabalin	Pregabalin	123	17
Atenolol	Atenolol	116	27
Potassium Chloride	Potassium Chloride	108	35
Warfarin Sodium	Warfarin Sodium	106	28
Sertraline Hcl	Sertraline Hcl	104	33
Escitalopram Oxalate	Escitalopram Oxalate	101	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	98	74
Clopidogrel	Clopidogrel Bisulfate	98	23
Glipizide Er	Glipizide	98	26
Citalopram Hbr	Citalopram Hydrobromide	97	21
Duloxetine Hcl	Duloxetine Hcl	96	24
Lorazepam	Lorazepam	92	16
Montelukast Sodium	Montelukast Sodium	92	32
Prednisone	Prednisone	91	46
Bupropion Xl	Bupropion Hcl	86	23
Venlafaxine Hcl Er	Venlafaxine Hcl	85	18
Allopurinol	Allopurinol	82	21
Finasteride	Finasteride	82	24
Azithromycin	Azithromycin	77	62
Clonazepam	Clonazepam	76	suppressed
Famotidine	Famotidine	76	26
Fluticasone Propionate	Fluticasone Propionate	73	31
Doxazosin Mesylate	Doxazosin Mesylate	70	15
Buspirone Hcl	Buspirone Hcl	69	25
Torsemide	Torsemide	66	19
Glimepiride	Glimepiride	65	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	63	13
Myrbetriq	Mirabegron	59	19
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	58	15
Pravastatin Sodium	Pravastatin Sodium	56	15
Alprazolam	Alprazolam	54	suppressed
Meloxicam	Meloxicam	53	16
Sucralfate	Sucralfate	53	19
Ropinirole Hcl	Ropinirole Hcl	51	14
Ozempic	Semaglutide	49	12
Mirtazapine	Mirtazapine	48	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	47	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	47	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	46	14
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	45	12
Nitroglycerin	Nitroglycerin	45	37
Ciprofloxacin Hcl	Ciprofloxacin Hcl	43	37
Paroxetine Hcl	Paroxetine Hcl	42	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	42	suppressed
Unifine Pentips	Pen Needle, Diabetic	42	16
Glipizide	Glipizide	41	13
Baclofen	Baclofen	39	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	39	11
Paxlovid	Nirmatrelvir/Ritonavir	39	38
Triamcinolone Acetonide	Triamcinolone Acetonide	39	26
Donepezil Hcl	Donepezil Hcl	36	13
Oxycodone Hcl	Oxycodone Hcl	36	11
Bupropion Hcl Sr	Bupropion Hcl	35	12
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	34	21
Meclizine Hcl	Meclizine Hcl	34	21
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	11
Diclofenac Sodium	Diclofenac Sodium	32	18
Amoxicillin	Amoxicillin	30	15
Novolog Flexpen	Insulin Aspart	30	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	30	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	29	29
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	14
Esomeprazole Magnesium	Esomeprazole Magnesium	28	suppressed
Nifedipine Er	Nifedipine	28	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	27	24
Nystatin	Nystatin	27	15
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Carvedilol	Carvedilol	26	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	suppressed
Ranolazine Er	Ranolazine	26	suppressed
Repaglinide	Repaglinide	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	22
Topiramate	Topiramate	24	suppressed
Digoxin	Digoxin	23	suppressed
Tradjenta	Linagliptin	23	suppressed
Cephalexin	Cephalexin	22	21
Diazepam	Diazepam	22	suppressed
Metolazone	Metolazone	22	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	22	suppressed
Raloxifene Hcl	Raloxifene Hcl	22	suppressed
Levofloxacin	Levofloxacin	21	18
Enalapril Maleate	Enalapril Maleate	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	20	15
Felodipine Er	Felodipine	19	suppressed
Sotalol	Sotalol Hcl	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Verapamil Er	Verapamil Hcl	19	suppressed
Calcitriol	Calcitriol	18	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Xultophy 100-3.6	Insulin Degludec/Liraglutide	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	12
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Valsartan	Valsartan	16	suppressed
Colchicine	Colchicine	15	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Cilostazol	Cilostazol	13	suppressed
Desloratadine	Desloratadine	13	suppressed
Dexilant	Dexlansoprazole	13	suppressed
Cimetidine	Cimetidine	12	suppressed
Colestipol Hcl	Colestipol Hcl	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	11
Fentanyl	Fentanyl	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	11	suppressed
Repatha Syringe	Evolocumab	11	suppressed
Verapamil Sr	Verapamil Hcl	11	suppressed
Xarelto	Rivaroxaban	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$13.98 · 1 records	Novo Nordisk Inc	Ozempic, Rybelsus	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error